Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lineage Cell Therapeutics, Inc.

< Previous 1 2 3 Next >
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Tickers LCTX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.